Company / Cash & Equivalents
Erasca, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$67.7M
FY2024
5-year range
$65.4M / $360.5M
FY2020-FY2024
Trend
-27.2%
vs FY2023
Sector context
#169 of 207
Health Care
What the data says
Erasca, Inc.'s cash & equivalents of $68M is lower than 82% of companies in the Health Care sector (FY2024). Cash & Equivalents has declined for 3 consecutive years, from $360M in FY2021 to $68M in FY2024.
Based on SEC 10-K filings.
$68M in FY2024 with a 3-year CAGR of -42.7%.
Declined from $284M to $68M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -42.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 207This company $67.7M Sector average $669.5M
▼
-89.9% below sector average
Key checks
Key Insights
- Erasca, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 3-year CAGR of -42.7%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 27.2% year-over-year.
- Ranks #169 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $67.7M | -27.2% |
| FY2023 | $93.1M | -67.3% |
| FY2022 | $284.2M | -21.2% |
| FY2021 | $360.5M | +451.4% |
| FY2020 | $65.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026